Modern Healthspan|21. Juli
Age-Reversing Stem Cell Treatment Succeeds in Human Trial | Dr Koji Tanabe
Dr. Koji Tanabe on Successful Age-Reversing Stem Cell Treatment in Human Trials
- Background: Dr. Koji Tanabe co-authored the seminal 2007 paper on induced pluripotent stem cells (iPSCs) under Nobel laureate Shinya Yamanaka, and now leads iPS Inc.
- What are iPSCs?: They are created by reprogramming adult cells (e.g., blood) with the four Yamanaka factors, resetting them to an “age zero” state similar to a fertilized egg. This erases epigenetic aging marks and lengthens telomeres.
- Efficiency: 20 years ago, only 1–2% of cells fully reprogrammed; today, over 80% achieve full reprogramming due to optimized gene balance and timing.
- Automation: iPS Inc. is developing a closed cassette system to mass-produce personalized iPSCs cost-effectively and sterily.
- Clinical Applications:
- Regenerative Medicine: iPSC-derived heart patches have been approved in Japan. Immune cells (NK cells) for cancer and beta cells for diabetes are in trials.
- Cell-Free Approach: Extracts from a patient’s own iPSCs are injected (e.g., into knees) in Japanese clinical studies, reducing pain and rejuvenating skin and hair.
- Safety: Autologous iPSCs (one’s own cells) are preferred to avoid risks of unknown viruses or immune reactions from donor cells. Strict quality control prevents tumor formation from partially reprogrammed cells.
- Concerns about In Vivo Reprogramming: Dr. Tanabe warns against directly injecting Yamanaka factors (e.g., via viruses) into the body, as this leads to uncontrolled, partial reprogramming, chaotic cell states, and elevated cancer risk.
- Future: In the short term, he expects aging slowdown via iPSC extracts and other technologies. Beyond 125 years, entirely new approaches would be needed.
- Takeaway: iPSCs are the “Intel Inside” for regenerative medicine – automation will make personalized treatments affordable.
